{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:46Z","timestamp":1792685986554,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"crossref","award":["68985113"],"award-info":[{"award-number":["68985113"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with Immune Mediated Inflammatory Diseases (IMIDs) using immunosuppressive therapy are at increased risk of infections, including vaccine-preventable infections. In this study, we aimed to evaluate whether patients with IMIDs on systemic immunosuppressive therapy are vaccinated according to current guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A survey was sent out, between August 2022 and March 2023, to all patients with IMIDs that visited the departments of dermatology, rheumatology and gastroenterology at an academic and regional hospital in Rotterdam, the Netherlands. Patient-reported vaccination status was compared to the Dutch guidelines on vaccinations in patients with chronic inflammatory diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 1,905\/5,987 patients responded to the survey (response rate 32%). After exclusion of patients without systemic immunosuppressive medication, the study population comprised 1,390 patients, median age 56 years (IQR 42\u201366) and 41% male. Most patients (92%) had been vaccinated according to the Dutch National Immunization Program. Before starting immunosuppressive therapy, 2% of the patients who were still considered at risk according to the Dutch guideline were vaccinated for measles, and 4% for diphtheria\/tetanus\/polio (DT-IPV). Additionally, 62% of patients received an annual influenza vaccine, 16% received a five-yearly pneumococcal vaccine, and 91% were fully vaccinated against COVID-19.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Patients with IMIDs on immunosuppressive therapy are not vaccinated in accordance with the guidelines. Implementation strategies to improve the vaccination rates for patients with IMIDs should specifically focus on vaccinating against measles and diphtheria\/tetanus\/polio, and periodic vaccination against pneumococcal and influenza infections.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s15010-024-02373-z","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:49:16Z","timestamp":1724424556000},"page":"317-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patients with immune mediated inflammatory diseases are insufficiently protected against vaccine-preventable infections"],"prefix":"10.1007","volume":"53","author":[{"given":"Natasja","family":"van de Pol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Janneke","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn B.A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia L.","family":"Schrauwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatos","family":"Cetin\u00f6zman-Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie C.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"2","key":"2373_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","volume":"155","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and opportunistic infections Associated with Treatment of Inflammatory Bowel diseases. Gastroenterology. 2018;155(2):337\u201346. e10.","journal-title":"Gastroenterology"},{"key":"2373_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2474-13-158","volume":"13","author":"WA Blumentals","year":"2012","unstructured":"Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158.","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"2373_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/ibd\/izy243","volume":"25","author":"A Tinsley","year":"2019","unstructured":"Tinsley A, Navabi S, Williams ED, Liu G, Kong L, Coates MD, Clarke K. Increased risk of Influenza and Influenza-Related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(2):369\u201376.","journal-title":"Inflamm Bowel Dis"},{"key":"2373_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","volume":"24","author":"M van Aalst","year":"2018","unstructured":"van Aalst M, L\u00f6tsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A, et al. Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis. Travel Med Infect Dis. 2018;24:89\u2013100.","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"2373_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/cid\/civ803","volume":"62","author":"A Shigayeva","year":"2016","unstructured":"Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, et al. Invasive pneumococcal Disease among Immunocompromised persons: implications for Vaccination Programs. Clin Infect Dis. 2016;62(2):139\u201347.","journal-title":"Clin Infect Dis"},{"key":"2373_CR6","unstructured":"Vaccinatie bij chronisch inflammatoire aandoeningen. Dutch Ministry of Health, Welfare and Sport; [ https:\/\/lci.rivm.nl\/richtlijnen\/vaccinatie-bij-chronisch-inflammatoire-aandoeningen#2-checklists-bij-vaccinatiezorg"},{"issue":"1","key":"2373_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2373_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443\u201368.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2373_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jaad.2013.06.046","volume":"69","author":"L Wine-Lee","year":"2013","unstructured":"Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis. J Am Acad Dermatol. 2013;69(6):1003\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"2373_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/ard.62.7.685","volume":"62","author":"MJ Bridges","year":"2003","unstructured":"Bridges MJ, Coady D, Kelly CA, Hamilton J, Heycock C. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(7):685.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2373_CR11","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1093\/rheumatology\/keab471","volume":"60","author":"I Colmegna","year":"2021","unstructured":"Colmegna I, Valerio V, Gosselin-Boucher V, Lacoste G, Labbe S, Lavoie KL, et al. Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study. Rheumatology (Oxford). 2021;60(11):5257\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"2373_CR12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/j.1572-0241.2006.00646.x","volume":"101","author":"GY Melmed","year":"2006","unstructured":"Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834\u201340.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2373_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.dld.2017.12.027","volume":"50","author":"P Loubet","year":"2018","unstructured":"Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: results from a web-based study. Dig Liver Dis. 2018;50(6):563\u20137.","journal-title":"Dig Liver Dis"},{"key":"2373_CR14","unstructured":"Adviesrapport. \u2018Vaccinatiezorg voor medische risicogroepen: wie neemt de regie?\u2019: Zorginstituut Nederland; 2021 [ https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2021\/06\/11\/advies-vaccinatiezorg-voor-medische-risicogroepen"},{"key":"2373_CR15","unstructured":"(CBS) DCBoS. 2019 [ https:\/\/www.cbs.nl\/nl-nl\/nieuws\/2019\/33\/verschil-levensverwachting-hoog-en-laagopgeleid-groeit\/opleidingsniveau"},{"issue":"7","key":"2373_CR16","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s10620-023-07903-7","volume":"68","author":"J Patel","year":"2023","unstructured":"Patel J, Noureldin M, Fakhouri D, Farraye FA, Kovar-Gough I, Warren B, et al. Interventions increase vaccination rates in inflammatory bowel disease and rheumatoid arthritis: a systematic review and Meta-analysis. Dig Dis Sci. 2023;68(7):2921\u201335.","journal-title":"Dig Dis Sci"},{"key":"2373_CR17","unstructured":"Dutch National Immunisation Programme. Dutch Ministry of Health, Welfare and Sport; [ https:\/\/rijksvaccinatieprogramma.nl\/english"},{"key":"2373_CR18","unstructured":"Coronavirus vaccination campaign in the Netherlands. Government of the Netherlands; [ https:\/\/www.government.nl\/topics\/coronavirus-covid-19\/dutch-vaccination-programme\/covid-19-vaccination-campaign"},{"issue":"8","key":"2373_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/MEG.0000000000002589","volume":"35","author":"C Abreu","year":"2023","unstructured":"Abreu C, Martins A, Branco E, Rocha R, Sarmento A, Magro F. Vaccines - beliefs and concerns: the voice of patients with inflammatory immunomediated diseases. Eur J Gastroenterol Hepatol. 2023;35(8):848\u201353.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"2373_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10067-020-05435-3","volume":"40","author":"V Valerio","year":"2021","unstructured":"Valerio V, Bazan MC, Wang M, Mazer BD, Pineau CA, Hazel EM, et al. A multimodal intervention increases influenza vaccine uptake in rheumatoid arthritis. Clin Rheumatol. 2021;40(2):575\u20139.","journal-title":"Clin Rheumatol"},{"issue":"30","key":"2373_CR21","doi-asserted-by":"publisher","first-page":"e29786","DOI":"10.1097\/MD.0000000000029786","volume":"101","author":"NJ Webb","year":"2022","unstructured":"Webb NJ, Lindsley J, Stockbridge EL, Workman A, Reynolds CD, Miller TL, et al. Effectiveness of an intervention to overcome influenza vaccine hesitancy in specialty clinic patients. Med (Baltim). 2022;101(30):e29786.","journal-title":"Med (Baltim)"},{"issue":"2","key":"2373_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/MIB.0000000000001013","volume":"23","author":"S Coenen","year":"2017","unstructured":"Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, et al. Effects of Education and Information on Vaccination Behavior in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(2):318\u201324.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"2373_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/ecco-jcc\/jjv064","volume":"9","author":"G Malhi","year":"2015","unstructured":"Malhi G, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, Nguyen GC. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9(6):439\u201344.","journal-title":"J Crohns Colitis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02373-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02373-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02373-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T19:48:58Z","timestamp":1739476138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02373-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2373"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02373-z","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of the EMC, MEC-2022-0196.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"CJW received grants from ZonMW, Falk and Pfizer, has received consulting fees from Janssen, Galapagos, and Pfizer, has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring and AbbVie and had leadership roles in the European Crohn\u2019s & Colitis organisation, United European Gastroenterology council and the Dutch Association for Gastroenterology (NVGE); MV received research funding\/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer; MBAvD reports grants and has served on the advisory board or as a speaker for Novartis and Janssen-Cilag. He has also has served on the advisory board or as a speaker for Abbvie, Leopharma, BMS, Celgene, Lilly, MSD, Pfizer, and Sanofi-Genzyme; RLW has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring, Pfizer, Galapagos, AbbVie and Janssen; ACV has served on advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, and Pfizer; all other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}